Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

[1]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[2]  T. Meyer,et al.  Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[3]  Hong Liu,et al.  Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. , 2019, Transplantation proceedings.

[4]  M. García-Fiñana,et al.  Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment , 2019, British Journal of Cancer.

[5]  Y. Hiasa,et al.  Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time‐dependent receiver operating characteristic , 2019, Journal of gastroenterology and hepatology.

[6]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[7]  M. Canale,et al.  Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? , 2018, World journal of gastroenterology.

[8]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[9]  Kelvin K. W. Chan,et al.  Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database , 2018, Cancer medicine.

[10]  A. Gasbarrini,et al.  Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice , 2018, Hepatology.

[11]  G. D'Ippolito,et al.  Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems , 2018, PloS one.

[12]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[13]  N. Caporaso,et al.  Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case–control study , 2018, Oncotarget.

[14]  Per Winkel,et al.  When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts , 2017, BMC Medical Research Methodology.

[15]  J. Bruix,et al.  Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. , 2017, Journal of hepatology.

[16]  G. Perrone,et al.  Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. , 2017, European journal of cancer.

[17]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[18]  R. Xu,et al.  Validation and ranking of seven staging systems of hepatocellular carcinoma , 2017, Oncology letters.

[19]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[20]  E. Van Cutsem,et al.  Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. Salmi,et al.  External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study , 2017, Hepatology.

[22]  M. Kudo,et al.  Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib , 2017, Oncotarget.

[23]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[24]  J. Marrero,et al.  Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. , 2016, Journal of hepatology.

[25]  M. Kurosaki,et al.  Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment , 2016, Liver Cancer.

[26]  J. Lund,et al.  Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma , 2016, The oncologist.

[27]  H. Komekado,et al.  Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. , 2016, Molecular and clinical oncology.

[28]  G. Spolverato,et al.  Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma , 2016, PLoS medicine.

[29]  M. Colombo,et al.  Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[30]  Joon-Oh Park,et al.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[31]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Fan,et al.  Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. , 2014, Gastroenterology.

[33]  A. Gasbarrini,et al.  The changing scenario of hepatocellular carcinoma in Italy: an update , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[34]  R. Bruno,et al.  Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[35]  M. Colombo,et al.  Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy , 2011, Hepatology.

[36]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[37]  Masatoshi Kudo,et al.  Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score , 2004, Hepatology.

[38]  K. Leung,et al.  Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system , 2002, Cancer.

[39]  M. Forster,et al.  Key Concepts in Model Selection: Performance and Generalizability. , 2000, Journal of mathematical psychology.

[40]  S. Chevret,et al.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. , 1999, Journal of hepatology.

[41]  D. Hosmer,et al.  A comparison of goodness-of-fit tests for the logistic regression model. , 1997, Statistics in medicine.

[42]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[43]  K. Rau,et al.  The ALBI grade predicts the prognosis of patients with advanced hepatocellular carcinoma received sorafenib , 2017 .

[44]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[45]  Bellia Mario,et al.  Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80) , 2000 .

[46]  C. Gonçalves,et al.  [Hepatocellular carcinoma]. , 1988, Arquivos de gastroenterologia.

[47]  C. G. Child,et al.  Surgery and portal hypertension. , 1964, Major problems in clinical surgery.